BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...inhibitor prochlorperazine with mAb therapies for cancer from University of Queensland...
...Therapeutics Inc. St. Jude Children's Research Hospital Sun Yat-sen University University of Queensland University...
BioCentury | Dec 15, 2020
Product Development

Dec. 14 COVID roundup: Phase III miss for Incyte-Novartis JAK inhibitor; Queensland vaccine program axed; plus Sputnik V final efficacy and Phase II starts for CureVac and Inovio

...nix Queensland vaccine programCSL Ltd. (ASX:CSL) will not run a Phase II/III trial of the University of Queensland’s...
...#), INCB018424 (Compound #), INC424 (Compound #), ruxolitinib (Generic), Jakavi (Other), Jakafi (Other) Gam-COVID-Vac Lyo CVnCoV INO-4800 Novartis AG Incyte Corp. University of Queensland CSL...
BioCentury | Dec 15, 2020
Product Development

Vaccines march forward & CAR Ts move earlier: a BioCentury podcast

...they had some manufacturing issues, and some dosing issues. And now we've also got the University of Queensland...
BioCentury | Jul 15, 2020
Product Development

University of Queensland COVID-19 vaccine becomes seventh with CEPI funding to enter the clinic

...vaccines continue to show progress as countermeasures against the virus. A CEPI-funded candidate from the University of Queensland...
...CD40L (CD40LG; CD154) - CD40 ligand Sandi Wong, Assistant Editor BNT162b1 PF-07302048 (BNT162) AdCOVID Coalition for Epidemic Preparedness Innovations (CEPI) Pfizer Inc. University of Queensland Tonix...
BioCentury | Jun 5, 2020
Product Development

Three CEPI-funded vaccines secure additional manufacturing resources

...flurry of vaccine updates also saw CEPI close a COVID-19 vaccine manufacturing deal with The University of Queensland...
...Queensland aboard vaccine train Also Thursday, CEPI closed a COVID-19 vaccine manufacturing deal with The University of Queensland...
...ChAdOx1) NVX-CoV2373 [MERGED] AstraZeneca plc GAVI, the Vaccine Alliance Bill & Melinda Gates Foundation World Health Organization University of Oxford Emergent BioSolutions Inc. University of Queensland CSL...
BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

...via its partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). Its partners include the University of Queensland...
BioCentury | Apr 29, 2020
Distillery Therapeutics

Inhibiting endocytosis to enhance cetuximab, trastuzumab and Bavencio antitumor efficacy

...Fiona Simpson, University of Queensland, Woolloongabba, Australia email: f.simpson@uq.edu.au Claire Quang Herceptin, trastuzumab (RG597) Erbitux, cetuximab (IMC-C225) Bavencio, avelumab (MSB0010718C, PF-06834635, Anti-PD-L1) University of Queensland...
BioCentury | Apr 17, 2020
Product Development

BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

...1018 adjuvant. Dynavax is also making CpG 1018 available to COVID-19 vaccine developers, including the University of Queensland...
BioCentury | Apr 4, 2020
Product Development

COVID-19 roundup: FDA’s expanded access program for convalescent plasma; plus more funding from BARDA, tests from Eurofins, BD-BioGx, and more

...Preparedness Innovations (CEPI), GSK has already made the adjuvant available to several groups including the University of Queensland...
BioCentury | Mar 27, 2020
Product Development

COVID-19 roundup: biopharmas scramble to reassess clinical timelines; plus CEPI-Dynavax, and emergency approvals for Vero, Fosun

...adjuvant, which is used in the company’s marketed HBV vaccine, Heplisav-B. The first partner, the University of Queensland...
Items per page:
1 - 10 of 131
BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

...inhibitor prochlorperazine with mAb therapies for cancer from University of Queensland...
...Therapeutics Inc. St. Jude Children's Research Hospital Sun Yat-sen University University of Queensland University...
BioCentury | Dec 15, 2020
Product Development

Dec. 14 COVID roundup: Phase III miss for Incyte-Novartis JAK inhibitor; Queensland vaccine program axed; plus Sputnik V final efficacy and Phase II starts for CureVac and Inovio

...nix Queensland vaccine programCSL Ltd. (ASX:CSL) will not run a Phase II/III trial of the University of Queensland’s...
...#), INCB018424 (Compound #), INC424 (Compound #), ruxolitinib (Generic), Jakavi (Other), Jakafi (Other) Gam-COVID-Vac Lyo CVnCoV INO-4800 Novartis AG Incyte Corp. University of Queensland CSL...
BioCentury | Dec 15, 2020
Product Development

Vaccines march forward & CAR Ts move earlier: a BioCentury podcast

...they had some manufacturing issues, and some dosing issues. And now we've also got the University of Queensland...
BioCentury | Jul 15, 2020
Product Development

University of Queensland COVID-19 vaccine becomes seventh with CEPI funding to enter the clinic

...vaccines continue to show progress as countermeasures against the virus. A CEPI-funded candidate from the University of Queensland...
...CD40L (CD40LG; CD154) - CD40 ligand Sandi Wong, Assistant Editor BNT162b1 PF-07302048 (BNT162) AdCOVID Coalition for Epidemic Preparedness Innovations (CEPI) Pfizer Inc. University of Queensland Tonix...
BioCentury | Jun 5, 2020
Product Development

Three CEPI-funded vaccines secure additional manufacturing resources

...flurry of vaccine updates also saw CEPI close a COVID-19 vaccine manufacturing deal with The University of Queensland...
...Queensland aboard vaccine train Also Thursday, CEPI closed a COVID-19 vaccine manufacturing deal with The University of Queensland...
...ChAdOx1) NVX-CoV2373 [MERGED] AstraZeneca plc GAVI, the Vaccine Alliance Bill & Melinda Gates Foundation World Health Organization University of Oxford Emergent BioSolutions Inc. University of Queensland CSL...
BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

...via its partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). Its partners include the University of Queensland...
BioCentury | Apr 29, 2020
Distillery Therapeutics

Inhibiting endocytosis to enhance cetuximab, trastuzumab and Bavencio antitumor efficacy

...Fiona Simpson, University of Queensland, Woolloongabba, Australia email: f.simpson@uq.edu.au Claire Quang Herceptin, trastuzumab (RG597) Erbitux, cetuximab (IMC-C225) Bavencio, avelumab (MSB0010718C, PF-06834635, Anti-PD-L1) University of Queensland...
BioCentury | Apr 17, 2020
Product Development

BARDA’s $483M commitment to Moderna headlines flurry of COVID-19 vaccine updates

...1018 adjuvant. Dynavax is also making CpG 1018 available to COVID-19 vaccine developers, including the University of Queensland...
BioCentury | Apr 4, 2020
Product Development

COVID-19 roundup: FDA’s expanded access program for convalescent plasma; plus more funding from BARDA, tests from Eurofins, BD-BioGx, and more

...Preparedness Innovations (CEPI), GSK has already made the adjuvant available to several groups including the University of Queensland...
BioCentury | Mar 27, 2020
Product Development

COVID-19 roundup: biopharmas scramble to reassess clinical timelines; plus CEPI-Dynavax, and emergency approvals for Vero, Fosun

...adjuvant, which is used in the company’s marketed HBV vaccine, Heplisav-B. The first partner, the University of Queensland...
Items per page:
1 - 10 of 131